Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q8WYR4
UPID:
RSPH1_HUMAN
Alternative names:
Cancer/testis antigen 79; Male meiotic metaphase chromosome-associated acidic protein; Meichroacidin; Testis-specific gene A2 protein
Alternative UPACC:
Q8WYR4; A8MWV0; B2RBN9; Q3MJA1
Background:
Radial spoke head 1 homolog (RSPH1), also known as Cancer/testis antigen 79, plays a crucial role in the motility of sperm and cilia by functioning as part of axonemal radial spoke complexes. This protein is pivotal in ensuring the proper movement and function of motile cilia, which are essential for various physiological processes.
Therapeutic significance:
Mutations in RSPH1 are linked to Ciliary dyskinesia, primary, 24, a disorder characterized by recurrent respiratory infections and chronic inflammation due to defects in respiratory cilia. Understanding the role of RSPH1 could open doors to potential therapeutic strategies for treating respiratory conditions stemming from ciliary dysfunction.